company background image
A006

Green Cross KOSE:A006280 Stock Report

Last Price

₩123.50k

Market Cap

₩1.4t

7D

0.8%

1Y

-61.9%

Updated

03 Oct, 2022

Data

Company Financials +
A006280 fundamental analysis
Snowflake Score
Valuation6/6
Future Growth1/6
Past Performance3/6
Financial Health5/6
Dividends2/6

A006280 Stock Overview

Green Cross Corporation, a biopharmaceutical company, develops drugs and vaccines in South Korea.

Green Cross Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Green Cross
Historical stock prices
Current Share Price₩123,500.00
52 Week High₩325,000.00
52 Week Low₩121,000.00
Beta1.26
1 Month Change-20.58%
3 Month Change-26.27%
1 Year Change-61.88%
3 Year Change8.81%
5 Year Change-38.40%
Change since IPO-58.50%

Recent News & Updates

Shareholder Returns

A006280KR BiotechsKR Market
7D0.8%-0.7%-6.1%
1Y-61.9%-48.4%-29.0%

Return vs Industry: A006280 underperformed the KR Biotechs industry which returned -48.4% over the past year.

Return vs Market: A006280 underperformed the KR Market which returned -29% over the past year.

Price Volatility

Is A006280's price volatile compared to industry and market?
A006280 volatility
A006280 Average Weekly Movement4.8%
Biotechs Industry Average Movement7.4%
Market Average Movement5.9%
10% most volatile stocks in KR Market10.6%
10% least volatile stocks in KR Market3.6%

Stable Share Price: A006280 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: A006280's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19672,084Il-Sup Huhhttps://www.globalgreencross.com

Green Cross Corporation, a biopharmaceutical company, develops drugs and vaccines in South Korea. The company provides plasma derivatives, including albumin, immunoglobulin, and antithrombin; and vaccines for hepatitis-B, Hantavirus hemorrhagic fever, influenza, flu, and varicella. It also offers prescription drugs for the bleeding symptom control and hemostasis for persons with hemophilia A; prevention and treatment of bleeding episodes induced by hemophilia A and post-operative treatment; and treatment of neutropenia, hunter syndrome, and liver cancer, as well as treatment of anti-inflammation, pain relief, and osteoarthritis.

Green Cross Fundamentals Summary

How do Green Cross's earnings and revenue compare to its market cap?
A006280 fundamental statistics
Market Cap₩1.41t
Earnings (TTM)₩124.74b
Revenue (TTM)₩1.71t

11.3x

P/E Ratio

0.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
A006280 income statement (TTM)
Revenue₩1.71t
Cost of Revenue₩1.11t
Gross Profit₩597.02b
Other Expenses₩472.28b
Earnings₩124.74b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)10.93k
Gross Margin34.95%
Net Profit Margin7.30%
Debt/Equity Ratio35.9%

How did A006280 perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

18%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is A006280 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A006280?

Other financial metrics that can be useful for relative valuation.

A006280 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.2x
Enterprise Value/EBITDA12.1x
PEG Ratio1.2x

Price to Earnings Ratio vs Peers

How does A006280's PE Ratio compare to its peers?

A006280 PE Ratio vs Peers
The above table shows the PE ratio for A006280 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average27.5x
22.3x25.2%₩1.2t
A005250 Green Cross Holdings
22.9xn/a₩732.4b
A086900 Medy-Tox
21.2x14.4%₩649.7b
A290650 L&C Bio
43.4xn/a₩543.3b
A006280 Green Cross
11.3x9.5%₩1.4t

Price-To-Earnings vs Peers: A006280 is good value based on its Price-To-Earnings Ratio (11.3x) compared to the peer average (27.5x).


Price to Earnings Ratio vs Industry

How does A006280's PE Ratio compare vs other companies in the KR Biotechs Industry?

Price-To-Earnings vs Industry: A006280 is good value based on its Price-To-Earnings Ratio (11.3x) compared to the KR Biotechs industry average (20.1x)


Price to Earnings Ratio vs Fair Ratio

What is A006280's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A006280 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio11.3x
Fair PE Ratio21.8x

Price-To-Earnings vs Fair Ratio: A006280 is good value based on its Price-To-Earnings Ratio (11.3x) compared to the estimated Fair Price-To-Earnings Ratio (21.8x).


Share Price vs Fair Value

What is the Fair Price of A006280 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A006280 (₩123500) is trading below our estimate of fair value (₩184334.22)

Significantly Below Fair Value: A006280 is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Green Cross forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


9.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: A006280's forecast earnings growth (9.5% per year) is above the savings rate (3.6%).

Earnings vs Market: A006280's earnings (9.5% per year) are forecast to grow slower than the KR market (17% per year).

High Growth Earnings: A006280's earnings are forecast to grow, but not significantly.

Revenue vs Market: A006280's revenue (3.7% per year) is forecast to grow slower than the KR market (9.6% per year).

High Growth Revenue: A006280's revenue (3.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: A006280's Return on Equity is forecast to be low in 3 years time (5.9%).


Discover growth companies

Past Performance

How has Green Cross performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


21.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: A006280 has a large one-off gain of ₩70.1B impacting its June 30 2022 financial results.

Growing Profit Margin: A006280's current net profit margins (7.3%) are higher than last year (6.2%).


Past Earnings Growth Analysis

Earnings Trend: A006280's earnings have grown significantly by 21.8% per year over the past 5 years.

Accelerating Growth: A006280's earnings growth over the past year (33.4%) exceeds its 5-year average (21.8% per year).

Earnings vs Industry: A006280 earnings growth over the past year (33.4%) underperformed the Biotechs industry 33.4%.


Return on Equity

High ROE: A006280's Return on Equity (9.3%) is considered low.


Discover strong past performing companies

Financial Health

How is Green Cross's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: A006280's short term assets (₩1,105.9B) exceed its short term liabilities (₩567.0B).

Long Term Liabilities: A006280's short term assets (₩1,105.9B) exceed its long term liabilities (₩424.0B).


Debt to Equity History and Analysis

Debt Level: A006280's net debt to equity ratio (22.4%) is considered satisfactory.

Reducing Debt: A006280's debt to equity ratio has increased from 28.9% to 35.9% over the past 5 years.

Debt Coverage: A006280's debt is well covered by operating cash flow (22%).

Interest Coverage: A006280's interest payments on its debt are well covered by EBIT (8.9x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Green Cross's current dividend yield, its reliability and sustainability?

Dividend Score

2/6

Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


1.62%

Current Dividend Yield

Dividend Yield vs Market

Green Cross Dividend Yield vs Market
How does Green Cross dividend yield compare to the market?
SegmentDividend Yield
Company (Green Cross)1.6%
Market Bottom 25% (KR)1.1%
Market Top 25% (KR)3.6%
Industry Average (Biotechs)0.7%
Analyst forecast in 3 Years (Green Cross)1.6%

Notable Dividend: A006280's dividend (1.62%) is higher than the bottom 25% of dividend payers in the KR market (1.14%).

High Dividend: A006280's dividend (1.62%) is low compared to the top 25% of dividend payers in the KR market (3.57%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, A006280 has been paying a dividend for less than 10 years.

Growing Dividend: A006280's dividend payments have increased, but the company has only paid a dividend for 6 years.


Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (18.3%), A006280's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its high cash payout ratio (135.3%), A006280's dividend payments are not well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Il-Sup Huh (68 yo)

13.75yrs

Tenure

Mr. Il-Sup Huh, Ph.D. has been the Chairperson of GC Pharma (formerly, Green Cross Corporation) since 2009 and serves as its Chief Executive Officer. Mr. Huh serves as Chairperson and Chief Executive Offic...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of A006280?
Owner TypeNumber of SharesOwnership Percentage
Employee Share Scheme4,4600.04%
Individual Insiders106,6960.9%
Institutions1,599,72914.0%
General Public3,851,81133.7%
Public Companies5,850,48251.3%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 65.55% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
51.26%
Green Cross Holdings Corporation
5,850,482₩722.5b0%no data
7.03%
National Pension Service
802,447₩99.1b0%0.06%
1.67%
The Vanguard Group, Inc.
190,995₩23.6b0.35%no data
1.38%
BlackRock, Inc.
157,019₩19.4b-0.1%no data
0.83%
J.P. Morgan Asset Management, Inc.
94,999₩11.7b0.05%no data
0.58%
Il-Sup Huh
66,173₩8.2b0%no data
0.56%
Norges Bank Investment Management
64,260₩7.9b0%no data
0.45%
Mogam Science Scholarship Foundation., Endowment Arm
50,910₩6.3b0%no data
0.24%
Eun-Cheol Hur
27,500₩3.4b0%no data
0.23%
TOBAM
26,102₩3.2b0%0.07%
0.2%
Bessemer Investment Management LLC
23,209₩2.9b0%no data
0.19%
Geode Capital Management, LLC
21,246₩2.6b3.97%no data
0.18%
Dimensional Fund Advisors LP
20,738₩2.6b-2.25%no data
0.12%
Charles Schwab Investment Management, Inc.
13,977₩1.7b0.57%no data
0.092%
Yong-Tae Park
10,455₩1.3b0%no data
0.086%
State Street Global Advisors, Inc.
9,793₩1.2b-14.35%no data
0.079%
Mirae Asset Global Investments Co., Ltd
9,018₩1.1b0%no data
0.072%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
8,238₩1.0b0%no data
0.053%
Deutsche Asset & Wealth Management
6,077₩750.5m0%no data
0.05%
Credit Suisse Asset Management (Switzerland)
5,704₩704.4m0%no data
0.046%
WisdomTree Asset Management, Inc.
5,226₩645.4m0.81%no data
0.039%
Green Cross Corp Employee Stock Ownership Association
4,460₩550.8m0%no data
0.036%
UBS Asset Management
4,074₩503.1m0%no data
0.035%
BNY Mellon Asset Management
3,997₩493.6m3.42%no data
0.035%
Amundi Asset Management
3,988₩492.5m-4.25%no data

Company Information

Green Cross Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Green Cross Corporation
  • Ticker: A006280
  • Exchange: KOSE
  • Founded: 1967
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₩1.410t
  • Shares outstanding: 11.41m
  • Website: https://www.globalgreencross.com

Number of Employees


Location

  • Green Cross Corporation
  • 107, Ihyeon-ro 30beon-gil
  • Giheung-gu
  • Yongin-Si
  • Gyeonggi-do
  • South Korea


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
A006280KOSE (Korea Stock Exchange)YesCommon StockKRKRWDec 1993

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/03 00:00
End of Day Share Price2022/09/30 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.